Denali launches with ex-Genentech management and $217m-deep pockets

15 May 2015

• By Sukaina Virji

Three ex-Genentech executives have secured whopping $217m to launch new company Denali Therapeutics focused on developing therapies for neurodegenerative diseases.

The creation of Denali is based on a collaboration between scientists, industry experts and investors, and is being driven by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

07 Aug 2025

• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Vertex’s Pain Drug Failure Adds To Investor Doubts

05 Aug 2025

• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

31 Jul 2025

• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

31 Jul 2025

• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.